PCMA releases statement on CMS Part D biosimilar substitution announcement
The Pharmaceutical Care Management Association (PCMA) released the following statement on the recent announcement from the Centers for Medicare and Medicaid Services (CMS) to allow Medicare Part D plans to substitute all FDA-approved biosimilars on their formularies.